Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-081-5 | CAS number: 52663-87-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
There is no specific test data available on potential reproductive toxic effect of the registered substance.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Work performed to OECD guidelines in 2009 and approved by the US Environmental Protection Agency Statement in report claiming the data covers range of alklyimines; specifically, "sodium and potassium salts of N-alkyl (C8-C18)-beta-iminodipropionic acid where the C8-C18 is linear and may be saturated and/or unsaturated, (CAS Reg. Nos. 110676-19-2, 3655-00-3, 61791-56-8, 14960-06-6, 26256-79-1, 90170-43-7, 91696-17-2, and 97862-48-1) [Ref 40 CFR Part 180, Federal Register Volume 76, number 24, 4 February 2011'
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- not specified
- Remarks:
- Claimed GLP but no detail
- Limit test:
- no
- Species:
- rat
- Strain:
- other: HanRcc:WIST (SPF)
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Details on mating procedure:
- Cohabitation
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Dosing began 14 days before mating and continued for 28 days for males and for day four of lactation for females
- Frequency of treatment:
- Daily
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 160 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 43 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10 males and 10 females per group
- Control animals:
- yes, concurrent no treatment
- Positive control:
- None
- Parental animals: Observations and examinations:
- Clinical signs daily (including maternal behaviour)
Functional observation battery (FOB)
Food consumption
Body weights
Blood sampling
Body temperature (during FOB) - Litter observations:
- Litter size and viabilty
- Postmortem examinations (parental animals):
- Yes
- Postmortem examinations (offspring):
- Yes, macroscopic examinations for malformation
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Taste aversion behaviour
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Yes, intermediate and high dose
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Yes, intermediate and high dose
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver and kidney
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance intake: Decrease in top groups pre-mating
- Reproductive performance:
- no effects observed
- Dose descriptor:
- NOEL
- Effect level:
- > 43 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: Reduced weight gain, adaptive changes to liver and kidneys
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 160 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: Reduced weight gain, adaptive changes to liver and kidneys
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 600 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- > 600 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects on litter size or viability No malformations reported
- Reproductive effects observed:
- not specified
- Conclusions:
- No treatment-related effects on litter size or survival were observed. No treatment-related effects on body weight were observed in offspring. Body weight gain was slightly decreased in males and females at 160 and 600 mg/kg/day, but there was no dose response.
No findings were observed on macroscopic examination of the offspring. The reproductive/developmental LOAEL for Sodium coco β-iminodipropionate in rats is not established.
The reproductive/developmental NOAEL is 600 mg/kg bw/day, the highest dose tested, in males and females. - Executive summary:
This EPA study is considered valid in terms of grouping of substances. Examination of data on various primary alkylamines show little difference in repeat toxicity effects, including reproduction, suggesting that there is minimal difference in terms of systemic toxicity between the different alklyamines, including branched and linear.
The comparison of sub-acute toxicity between the tested substance and the result of this EPA study are consistent and read-across is considered valid; the EPA study shows slightly more adverse effects than the Key Study (on the registered substance) over 28 days and is therefore considered a suitable surrogate for the reporting of reproductive effects.
Reference
Tubular degeneration/regeneration and hyaline droplets/granulation of the kidneys in males
Follicular hypertrophy of the thyroid in males and females
Acanthosis of the non-glandular stomach in males and females
Inflammation of the non-glandular stomach in males; and congestion, thrombosis and inflammation of the glandular stomach in females
No abnormalities reported
No treatment-related effects on litter size or survival were observed. No treatment-related effects on body weight were observed in offspring. Body weight gain was slightly decreased in males and females at 160 and 600 mg/kg/day, but there was no dose response.
No findings were observed on macroscopic examination of the offspring. The reproductive/developmental LOAEL for Sodium coco β-iminodipropionate in rats is not established.
The reproductive/developmental NOAEL is 600 mg/kg bw/day, the highest dose tested, in males and females.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The US EPA review of Sodium Salts of N-Alkyl (C8-C18)-β-iminodipropionic Acid (SSNA) includes testing of the coco- derivative for reproductive toxicity screening. This shows parental toxicity effects, but no adverse effects on reproductive parameters. The EPA review concludes;
The parental systemic LOAEL for Sodium coco β-iminodipropionate in rats is 160 mg/kg bw/day, based on decreased body weight gain in males and females during the pre-mating period, and an increased incidence of microscopic lesions in the kidneys of males and glandular and acanthosis of the non-glandular stomach of females. The parental systemic NOAEL is 43 mg/kg bw/day.
No treatment-related effects on litter size or survival were observed. No treatment-related effects on body weight were observed in offspring. No findings were observed on macroscopic examination of the offspring.
Short description of key information:
Parental LOAEL= 160 mg/kg bw/day based on decreased body weight gain in males and females during the pre-mating period, and an increased incidence of microscopic lesions in the kidneys of males and acanthosis of the glandular + non-glandular stomachs of females.
Reproductive/ Developmental LOAEL was not observed.
Justification for selection of Effect on fertility via oral route:
Since there is no specific test data on potential reproductive toxic effect of Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, reference is made to a US Government review on this class of material used as cosmetic ingredients. In view of primary cosmetic use, it is considered that further animal testing is not appropriate and would be contrary to European principles.
Justification for selection of Effect on fertility via inhalation route:
Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 is a paste with a low vapour pressure of < 1.5 mPa at 20°C, so it is not considered to be scientifically valid to conduct an inhalation study.
Justification for selection of Effect on fertility via dermal route:
Based on the physicochemical properties of Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, it is considered very unlikely that dermal absorption would exceed oral absorption, so it is not considered relevant to conduct a dermal study.
Effects on developmental toxicity
Description of key information
There is no specific test data available on potential developmental toxicity of the registered substance. The US EPA review of Sodium Salts of N-Alkyl (C8-C18)-β-iminodipropionic Acid resulted in parental LOAEL= 160 mg/kg bw/day based on decreased body weight gain in males and females during the pre-mating period, and an increased incidence of microscopic lesions in the kidneys of males and acanthosis of the glandular + non-glandular stomachs of females. Reproductive/ Developmental LOAEL was not observed.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see remark
- Remarks:
- Work performed to OECD guidelines in 2009 and approved by the US Environmental Protection Agency Statement in report claiming the data covers range of alklyimines; specifically, "sodium and potassium salts of N-alkyl (C8-C18)-beta-iminodipropionic acid where the C8-C18 is linear and may be saturated and/or unsaturated, (CAS Reg. Nos. 110676-19-2, 3655-00-3, 61791-56-8, 14960-06-6, 26256-79-1, 90170-43-7, 91696-17-2, and 97862-48-1) [Ref 40 CFR Part 180, Federal Register Volume 76, number 24, 4 February 2011'
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developme ntal Toxicity Screening Test)
- GLP compliance:
- not specified
- Remarks:
- Claimed GLP but no detail
- Limit test:
- no
- Species:
- rat
- Strain:
- other: other: HanRcc:WIST (SPF)
- Route of administration:
- oral: gavage
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Dosing began 14 days before mating and continued for 28 days for males and for day four of lactation for females
- Frequency of treatment:
- Daily
- Duration of test:
- 28 days
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 160 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 43 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10 males and 10 females per group
- Control animals:
- yes, concurrent no treatment
- Maternal examinations:
- Parental animals: Observations and examinations
Clinical signs daily (including maternal behaviour)
Functional observation battery (FOB)
Food consumption
Body weights
Blood sampling
Body temperature (during FOB)
Litter observations
Litter size and viabilty
Postmortem examinations (parental animals)
Yes - Fetal examinations:
- Yes, macroscopic examinations for malformation
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Taste aversion behaviour
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Yes, intermediate and high dose
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Yes, intermediate and high dose
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Changes in liver in higher dose animals
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver and kidney
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver and kidney
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance intake: Decrease in top groups pre-mating
- Dose descriptor:
- NOEL
- Remarks:
- male/female
- Effect level:
- > 43 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Basis for effect level:
- other: Reduced weight gain, adaptive changes to liver and kidneys
- Dose descriptor:
- NOAEL
- Remarks:
- male/female
- Effect level:
- ca. 160 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Basis for effect level:
- other: Reduced weight gain, adaptive changes to liver and kidneys
- Dose descriptor:
- LOAEL
- Remarks:
- male/female
- Effect level:
- ca. 600 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Basis for effect level:
- other: see remark
- Abnormalities:
- no effects observed
- Description (incidence and severity):
- Reported effects were considered to be caused by systemic toxicity and did not affect reproductive performance
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed - Reduction in number of live offspring:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- External malformations:
- not specified
- Skeletal malformations:
- not specified
- Visceral malformations:
- not specified
- Other effects:
- no effects observed
- Description (incidence and severity):
- No clinical signs observed
- Details on embryotoxic / teratogenic effects:
- No adverse effects on litter size or viability. No abnormalities reported.
- Dose descriptor:
- NOAEL
- Effect level:
- > 600 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects on litter size or viability. No malformations reported.
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Conclusions:
- No treatment-related effects on litter size or survival were observed. No treatment-related effects on body weight were observed in offspring. Body weight gain was slightly decreased in males and fem ales at 160 and 600 mg/kg/day, but there was no dose response.
No findings were observed on macroscopic examination of the offspring. The reproductive/developmental LOAEL for Sodium coco β-iminodipropionate in rats is not established.
The reproductive/developmental NOAEL is 600 mg/kg bw/day, the highest dose tested, in males and females. - Executive summary:
This EPA study is considered valid in terms of grouping of substances. Examination of data on various primary alkylamines show little difference in repeat toxicity effects, including reproduction, suggesting that there is minimal difference in terms of systemic toxicity between the different alklyamines, including
branched and linear.
The comparison of sub-acute toxicity between the tested substance and the result of this EPA study are consistent and read-across is considered valid; the EPA study shows slightly more adverse effects than the Key Study (on the registered substance) over 28 days and is therefore considered a suitable surrogate for the reporting of reproductive effects.
Reference
No treatment-related effects on litter size or survival were observed. No treatment-related effects on body weight were observed in offspring. Body weight gain was slightly decreased in males and females at 160 and 600 mg/kg/day, but there was no dose response.
No findings were observed on macroscopic examination of the offspring. The reproductive/ developmental LOAEL for Sodium coco β-iminodipropionate in rats is not established.
The reproductive/developmental NOAEL is 600 mg/kg bw/day, the highest dose tested, in males and females.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Justification for selection of Effect on developmental toxicity: via oral route:
Since there is no specific test data on potential reproductive toxic effect of Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, [more]
Justification for selection of Effect on developmental toxicity: via inhalation route:
Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 is a paste with a low vapour pressure of < 1.5 mPa at 20°C, so it is not considered to be scientifically valid to conduct an inhalation study.
Justification for selection of Effect on developmental toxicity: via dermal route:
Based on the physicochemical properties of Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, it is considered very unlikely that dermal absorption would exceed oral absorption, so it is not considered relevant to conduct a dermal study.
Toxicity to reproduction: other studies
Additional information
The US EPA review of Sodium Salts of N-Alkyl (C8-C18)-β-iminodipropionic Acid (SSNA) includes testing of the coco- derivative for reproductive toxicity screening. This shows parental toxicity effects, but no adverse effects on reproductive parameters. The EPA review concludes;
The parental systemic LOAEL for Sodium coco β-iminodipropionate in rats is 160 mg/kg bw/day, based on decreased body weight gain in males and females during the pre-mating period, and an increased incidence of microscopic lesions in the kidneys of males and glandular and acanthosis of the non-glandular stomach of females. The parental systemic NOAEL is 43 mg/kg bw/day.
No treatment-related effects on litter size or survival were observed. No treatment-related effects on body weight were observed in offspring. No findings were observed on macroscopic examination of the offspring.
Justification for classification or non-classification
No adverse effects were observed in terms of reproductive performance, litter size or viability of the young.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.